Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

Study (n=208,757) found that compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with increased risk for DKA (incidence rate, 2.03 [CI, 1.83 to 2.25] vs 0.75 [CI, 0.63 to 0.89]; HR, 2.85 [CI, 1.99 to 4.08]) and molecule-specific analyses suggest a class effect.


Annals of Internal Medicine